scholarly article | Q13442814 |
P356 | DOI | 10.1002/SIM.1909 |
P8608 | Fatcat ID | release_nxftk2rdxjailb7spp6u644gvu |
P698 | PubMed publication ID | 15490432 |
P50 | author | Nick C. Fox | Q37836499 |
Michael G. Kenward | Q58619221 | ||
Chris Frost | Q84173613 | ||
P2860 | cites work | Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease | Q27860795 |
P433 | issue | 21 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 3275-3286 | |
P577 | publication date | 2004-11-01 | |
P1433 | published in | Statistics in Medicine | Q7604438 |
P1476 | title | The analysis of repeated 'direct' measures of change illustrated with an application in longitudinal imaging | |
P478 | volume | 23 |
Q33726079 | A Comparison of Accelerated and Non-accelerated MRI Scans for Brain Volume and Boundary Shift Integral Measures of Volume Change: Evidence from the ADNI Dataset. |
Q36251868 | Assessing atrophy measurement techniques in dementia: Results from the MIRIAD atrophy challenge |
Q33540910 | Automated cross-sectional and longitudinal hippocampal volume measurement in mild cognitive impairment and Alzheimer's disease |
Q36661880 | Cerebral atrophy in mild cognitive impairment and Alzheimer disease: rates and acceleration |
Q48414068 | Combining short interval MRI in Alzheimer's disease: Implications for therapeutic trials |
Q33565800 | Comparison of phantom and registration scaling corrections using the ADNI cohort |
Q47866122 | Deep grey matter volume loss drives disability worsening in multiple sclerosis. |
Q45304194 | Design optimization for clinical trials in early-stage manifest Huntington's disease |
Q47265537 | Detecting treatment effects on brain atrophy in relapsing remitting multiple sclerosis: sample size estimates |
Q29012779 | Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial |
Q36167476 | Estimating anatomical trajectories with Bayesian mixed-effects modeling |
Q34081836 | In vivo evidence of glutamate toxicity in multiple sclerosis |
Q91969017 | Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial |
Q33766180 | Large deformation diffeomorphism and momentum based hippocampal shape discrimination in dementia of the Alzheimer type |
Q61910897 | MACUSTAR: Development and Clinical Validation of Functional, Structural, and Patient-Reported Endpoints in Intermediate Age-Related Macular Degeneration |
Q37258575 | MIRIAD--Public release of a multiple time point Alzheimer's MR imaging dataset |
Q33759240 | Mapping Alzheimer's disease progression in 1309 MRI scans: power estimates for different inter-scan intervals |
Q34457231 | Now you hear it, now you don't: transient traces of consonants and their nonspeech analogues in the human brain |
Q47342494 | Patterns of progressive atrophy vary with age in Alzheimer's disease patients. |
Q39138281 | Presymptomatic atrophy in autosomal dominant Alzheimer's disease: A serial MRI study. |
Q53032916 | Reliability and sensitivity of visual scales versus volumetry for evaluating white matter hyperintensity progression. |
Q30354417 | Sample Size Estimation for Alzheimer's Disease Trials from Japanese ADNI Serial Magnetic Resonance Imaging. |
Q33384098 | Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis |
Q34081087 | Sex and age differences in atrophic rates: an ADNI study with n=1368 MRI scans |
Q48417159 | Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study |
Q48457345 | Volume changes in Alzheimer's disease and mild cognitive impairment: cognitive associations |
Search more.